

# 1 SNORD90 induces glutamatergic signaling following treatment with 2 monoaminergic antidepressants

## 4 AUTHORS

5 Rixing Lin<sup>1,2,†</sup>, Aron Kos<sup>3,4,5,†</sup>, Juan Pablo Lopez<sup>3,4,5</sup>, Julien Dine<sup>3,4,5</sup>, Laura M. Fiori<sup>1</sup>, Jennie  
6 Yang<sup>1</sup>, Yair Ben-Efraim<sup>3,4,5</sup>, Zahia Aouabed<sup>1</sup>, Pascal Ibrahim<sup>1,2</sup>, Haruka Mitsuhashi<sup>1,2</sup>, Tak Pan  
7 Wong<sup>6,7</sup>, El Cherif Ibrahim<sup>8</sup>, Catherine Belzung<sup>9</sup>, Pierre Blier<sup>10</sup>, Faranak Farzan<sup>11</sup>, Benicio N.  
8 Frey<sup>12,13</sup>, Raymond W. Lam<sup>14</sup>, Roumen Milev<sup>15</sup>, Daniel J. Müller<sup>16,17</sup>, Sagar V. Parikh<sup>18</sup>, Claudio  
9 Soares<sup>15</sup>, Rudolf Uher<sup>19,20</sup>, Corina Nagy<sup>1</sup>, Naguib Mechawar<sup>1</sup>, Jane A. Foster<sup>12,13,16</sup>, Sidney H.  
10 Kennedy<sup>16,21</sup>, Alon Chen<sup>3,4,5\*</sup>, and Gustavo Turecki<sup>1\*</sup>

## 12 AFFILIATIONS

13 <sup>1</sup>McGill Group for Suicide Studies, Douglas Mental Health University Institute, Department of  
14 Psychiatry, McGill University; Montreal, QC, Canada

15 <sup>2</sup>Integrated Program in Neuroscience, McGill University; Montreal, QC, Canada

16 <sup>3</sup>Department of Stress Neurobiology and Neurogenetics, Max Planck Institute of Psychiatry;  
17 Munich, Germany

18 <sup>4</sup>Department of Brain Sciences, Weizmann Institute of Science; Rehovot, Israel

19 <sup>5</sup>Department of Molecular Neuroscience, Weizmann Institute of Science; Rehovot, Israel

20 <sup>6</sup>Neuroscience Division, Douglas Research Centre; Montreal, QC, Canada.

21 <sup>7</sup>Department of Psychiatry, McGill University; Montreal, QC, Canada.

22 <sup>8</sup>Aix-Marseille Université, CNRS, INT, Institute Neuroscience Timone; Marseille, France

23 <sup>9</sup>UMR 1253, iBrain, UFR Sciences et Techniques; Parc Grandmont, Tours, France

24 <sup>10</sup>Mood Disorders Research Unit, University of Ottawa Institute of Mental Health Research;  
25 Ottawa, Ontario, Canada.

26 <sup>11</sup>eBrain Lab, Simon Fraser University; Surrey, British Columbia, Canada

27 <sup>12</sup>Department of Psychiatry and Behavioural Neurosciences, McMaster University; Hamilton,  
28 ON, Canada

29 <sup>13</sup>Mood Disorders Program, St. Joseph's Healthcare Hamilton; Hamilton, ON, Canada

30 <sup>14</sup>Department of Psychiatry, University of British Columbia; Vancouver, British Columbia,  
31 Canada

32 <sup>15</sup>Departments of Psychiatry and Psychology, Queens University, Providence Care; Kingston,  
33 Ontario, Canada

34 <sup>16</sup>Department of Psychiatry, University Health Network, Krembil Research Institute, University  
35 of Toronto; Toronto, Ontario, Canada

36 <sup>17</sup>Centre for Addiction and Mental Health; Toronto, Ontario, Canada

37 <sup>18</sup>Department of Psychiatry, University of Michigan; Ann Arbor, Michigan, USA

38 <sup>19</sup>Nova Scotia Health Authority; Halifax, NS, Canada

39 <sup>20</sup>Department of Psychiatry, Dalhousie University; Halifax, Nova Scotia, Canada

40 <sup>21</sup>St Michael's Hospital, Li Ka Shing Knowledge Institute, Centre for Depression and Suicide  
41 Studies; Toronto, Ontario, Canada

42  
43 †These authors contributed equally to this work

44  
45 \*Corresponding author. Email: [gustavo.turecki@mcgill.ca](mailto:gustavo.turecki@mcgill.ca)

46

47 **ABSTRACT**

48 Most available antidepressants target the serotonergic system, selectively or non-selectively, and  
49 yield slow and inconsistent clinical responses, whereas the monoamine changes they elicit do not  
50 correlate with treatment response. Recent findings point to the glutamatergic system as a target  
51 for rapid acting antidepressants. Investigating different cohorts of depressed individuals treated  
52 with serotonergic and other monoaminergic antidepressants, we found that the expression of a  
53 small nucleolar RNA, SNORD90, was elevated following treatment response. When we  
54 increased SNORD90 levels in the mouse anterior cingulate cortex (ACC), a brain region  
55 regulating mood responses, we observed antidepressive-like behaviors. We identified neuregulin  
56 3 (NRG3) as one of the targets of SNORD90, which we show is regulated through the  
57 accumulation of N6-methyladenosine modifications leading to YTHDF2 mediated RNA decay.  
58 We further demonstrate that a decrease in NRG3 expression resulted in increased glutamatergic  
59 release in the mouse ACC. These findings support a molecular link between monoaminergic  
60 antidepressant treatment and glutamatergic neurotransmission.

61

62 **INTRODUCTION:**

63 Antidepressants are the first line treatment for major depressive disorder (MDD), collectively  
64 accounting for one of the most prescribed medications (1). However, response to antidepressant  
65 treatment is variable with less than 50% of patients responding to first trial, and up to 40% with  
66 no clinical response after two or more trials (2). While most currently available antidepressants  
67 act by selectively or non-selectively targeting serotonergic receptors the exact mechanisms by  
68 which they effect mood changes and improvements in depression remain unknown. Importantly,  
69 although the enhancement of monoamine function, in particular serotonin, can be observed  
70 within hours after antidepressant drug administration, clinical improvements are not observed  
71 until days or weeks following antidepressant treatment initiation (3-5). The delayed clinical  
72 response led researchers to study underlying neurobiological adaptations to understand  
73 mechanisms of antidepressant response. Monoamines have been a focus of depression studies  
74 since most treatment options target this system. However, given the delayed clinical response  
75 other neurotransmitter systems have been gaining interest in depression and particularly the  
76 glutamatergic system, which is believed to be the target of rapid acting antidepressants (6, 7).  
77 Moreover, recent evidence suggest that monoaminergic antidepressants may act by modulating  
78 the glutamatergic system, although it is still unclear through what molecular mechanisms (8, 9).

79  
80 In this study, we identified a molecular mechanism whereby monoaminergic antidepressants  
81 produce an effect on glutamatergic neurotransmission. We found elevated levels of a small  
82 nucleolar RNA (snoRNA), SNORD90, in response to antidepressant drug exposure and report  
83 that SNORD90 guides N6-methyladenosine (m6A) modifications onto neuregulin 3 (NRG3),

84 which in turn lead to YTHDF2-mediated down-regulation of NRG3 expression and subsequent  
85 increases in glutamatergic release.

86

## 87 **RESULTS:**

### 88 **SNORD90 levels are increased in response to monoaminergic antidepressants**

89 We initially examined snoRNA expression using small RNA-sequencing data from peripheral  
90 blood samples collected from three independent antidepressant clinical trials (discovery cohort,  
91 replication cohort 1 and replication cohort 2) administering duloxetine, escitalopram, or  
92 desvenlafaxine. To identify snoRNAs associated with treatment response, we focused our  
93 attention on snoRNAs that were differentially expressed between baseline (T0) and eight weeks  
94 after treatment (T8), when clinical outcome was ascertained. In doing so, we identified nine  
95 snoRNAs in our placebo controlled double blind discovery cohort that had a significant  
96 interaction ( $p < 0.05$ ) between time (T0/T8) and treatment outcome (response/non-response)  
97 (figure 1A & supplemental table 1-3). In particular, SNORD90 was the only snoRNA that was  
98 consistently up-regulated after antidepressant treatment in subjects who responded to treatment  
99 across all three independent cohorts (figure 1B & supplemental figure 1). As such, we further  
100 investigated SNORD90.

101

102 To better understand if SNORD90 expression has similar changes in the brain following  
103 antidepressant treatment as observed in peripheral tissue, we investigated human post-mortem  
104 anterior cingulate cortex (ACC), a brain region that plays an important role in the regulation of  
105 mood (10, 11). We studied individuals who died while affected with MDD and were or were not  
106 treated with antidepressants. We observed a specific up-regulation of SNORD90 in individuals

107 who were depressed when they died and were actively treated with antidepressants (figure 1C).  
108 To follow up these results, we investigated the expression of Snord90 in an unpredicted chronic  
109 mild stress (UCMS) mouse model, which is commonly used to study depressive-like behaviors  
110 in mice. Mice were subjected to UCMS, followed by administration of fluoxetine (12). We  
111 specifically profiled the mouse cingulate area 1/2 (cg1/2), a region that is equivalent to the  
112 human ACC. Similar to the results observed in humans, we observed a specific up-regulation of  
113 Snord90 in the ACC of mice that underwent the UCMS paradigm followed by antidepressant  
114 administration, whereas UCMS or antidepressant administration alone did not alter the  
115 expression of Snord90 (figure 1D). To assess if the effects observed on the expression of  
116 SNORD90 were specific to antidepressants or common to other drugs, we treated human  
117 neuronal cells derived from iPSCs and differentiated to a monoaminergic phenotype with several  
118 psychotropic drugs, including duloxetine, escitalopram, haloperidol, lithium, or non-  
119 psychotropic drugs (aspirin) and regular culture media. We observed that SNORD90 expression  
120 was up-regulated exclusively by antidepressant drugs, while other treatments did not  
121 significantly alter SNORD90 expression (figure 1E). Together our data suggests that  
122 antidepressant treatment response associates with an increase in SNORD90 expression.

123

#### 124 **SNORD90 over-expression in mouse ACC induces anti-depressive like behaviours**

125 Given that we observed an upregulation of SNORD90 with antidepressant treatment response in  
126 humans and mice, we next investigated if the over-expression of Snord90 in the cg 1/2 cortex of  
127 mice has behavioural implications. We over-expressed (OE) Snord90 or a full scrambled  
128 Snord90 sequence control in the mouse cg1/2 via bilateral injections of an adeno-associated virus  
129 (AAV) followed by a battery of behavioural tests designed to measure anxiety and depressive-

130 like behaviors in mice (figure 2A). We did not observe any differences in the total distance  
131 traveled in the open field test, which indicated no general locomotor differences between  
132 Snord90 OE and full scramble OE (figure 2B). Snord90 OE increased the amount of time spent  
133 in the open arm and decreased the amount of time spent in the closed arm of the elevated plus  
134 maze (figure 2C). Moreover, Snord90 OE increased time spent grooming after splashing with  
135 10% sucrose solution and increased time spent struggling in the tail suspension test (figure 2D-  
136 E). Lastly, we calculated an integrated emotionality Z-score by combining data from the elevated  
137 plus maze, splash test, and tail suspension test (figure 2F). Overall, our results consistently  
138 showed that over-expressing SNORD90 levels in *cg1/2* yielded decreased emotionality  
139 indicative of a decrease in anxiety-like and depressive-like behaviours (figure 2F).

140

### 141 **SNORD90 directly down-regulates NRG3**

142 SNORD90 is subcategorized as an orphan snoRNA as it does not have any canonical rRNA,  
143 snRNA, or tRNA targets (13). However, more recent studies have indicated that some snoRNAs  
144 exhibit atypical functioning such as regulation of alternative splicing and modulating expression  
145 of mRNA (14-16). Thus, we explored possible RNA targets for SNORD90 using the basic local  
146 alignment (BLAST) search tool for base complementarity, and using the C/D box snoRNA target  
147 prediction tool “PLEXY” (17). Using these in-silico methods we identified NRG3 as a putative  
148 gene target for SNORD90 (figure 3A & supplementary table 4-5). More specifically, we  
149 identified three predicted binding regions for SNORD90 on the NRG3 pre-mRNA (pre-NRG3)  
150 (figure 3A & supplementary table 4-5). NRG3 is a growth factor that is part of the neuregulin  
151 family and that is highly enriched in the brain and has been previously associated with  
152 psychiatric phenotypes (18-20). To determine if SNORD90 regulates NRG3, we first assessed

153 NRG3 expression in the same human and mouse ACC samples, as well as in the neuronal  
154 cultures described above (supplementary figure 2A-C). We observed a negative correlation  
155 between SNORD90 and NRG3 in all three experimental contexts (supplementary figure 2D-F),  
156 and interestingly, we observed the most significant differences in direction of fold-change  
157 between SNORD90 and NRG3 expression in groups with antidepressant drug exposure  
158 (supplementary figure 2G-I).

159  
160 To further investigate the relationship between SNORD90 and NRG3, we over-expressed  
161 SNORD90 in human neural progenitor cells (NPCs) and assessed the resulting effects on NRG3  
162 expression (supplementary figure 3A-B). We constructed AAV vectors expressing wild-type  
163 SNORD90 (SNORD90 OE), as well as two scrambled controls (supplementary figure 3A). The  
164 first control had a scramble sequence in the central region of the SNORD90 transcript, where the  
165 predicted complementary sequence to NRG3 lies (seed scramble OE) and the second control had  
166 a full scramble of the entire SNORD90 transcript (full scramble OE) (supplementary figure 3A).  
167 SNORD90 OE resulted in a ~50% decrease in NRG3 expression at both the mRNA and protein  
168 levels (figure 3B and supplementary figure 3C). Seed scramble OE and full scramble OE did not  
169 alter the expression of NRG3, indicating the region of predicted complementarity between  
170 SNORD90 and NRG3 plays an important role in the ability of SNORD90 to down-regulate  
171 NRG3 (figure 3B). We also measured the expression of pre-NRG3, since our in-silico  
172 predictions indicated that SNORD90 is primarily interacting with intronic regions of pre-NRG3,  
173 however, pre-NRG3 expression was not altered by SNORD90 OE or any of the scrambled  
174 controls (supplementary figure 3D). We next examined the effects of SNORD90 knock-down  
175 (KD) using antisense oligonucleotides (ASO) (supplementary figure 4A-B). We screened four

176 ASOs that target different regions of SNORD90 and selected the ASO achieving the best KD  
177 (supplemental figure 4A-B). SNORD90 KD by approximately 55% resulted in a ~50%  
178 upregulation of NRG3 expression (figure 3C). We again did not observe any significant changes  
179 at the level of pre-mRNA expression (supplementary figure 4C). Finally, to further confirm the  
180 importance of direct interaction between SNORD90 and NRG3, we designed target blockers  
181 which have sequence complementarity to the predicted SNORD90 binding sites on pre-NRG3  
182 (figure 3D). Target blockers were co-transfected with our SNORD90 OE vectors (figure 3D).  
183 Interestingly, when each individual site was blocked, we observed a partial rescue of NRG3  
184 expression (figure 3E). However, simultaneously blocking all three predicted sites was required  
185 for a complete rescue of the downregulation effects of SNORD90 OE (figure 3E). Pre-NRG3  
186 expression was not altered by any target blockers (supplementary figure 5). Together our data  
187 suggests that SNORD90 directly down-regulates NRG3 expression through multiple interaction  
188 sites on intronic regions.

189

### 190 **SNORD90 associates with RBM15B and guides m6A modifications onto NRG3**

191 We next asked what mechanisms may explain SNORD90's effects on NRG3 given that it  
192 interacts with intronic regions of NRG3, and yet, it does not affect pre-mRNA levels of NRG3.  
193 Since SNORD90 displays atypical functioning, we posited that it could regulate NRG3 through  
194 the recruitment of a unique set of RNA binding proteins (RBPs) that is different from  
195 canonically functioning C/D box snoRNAs (21). Using the in-silico tool "oRNament" we  
196 identified a sequence-motif for RNA Binding Motif Protein 15B (RBM15B); this motif sequence  
197 was further confirmed by Van Nostrand et al., 2020 (22, 23) (supplemental table 6). RBM15B is  
198 a key regulator of RNA N6-methyladenosine (m6A) modifications by facilitating interactions



199 with Wilms' tumor 1-associating protein (WTAP), which in turn binds to methyltransferase like  
200 3 (METTL3) forming a major m6A writer complex (24). To confirm the association of  
201 SNORD90 with RBM15B, we performed RNA immunoprecipitation (RIP) against RBM15B as  
202 well as the canonical core enzymatic protein for C/D snoRNAs, Fibrillarin (figure 4A) (25, 26).  
203 We observed a significantly higher level of association of SNORD90 to RBM15B compared to  
204 fibrillarin whereas a canonically functioning snoRNA, SNORD44, displayed enrichment for  
205 fibrillarin IP (figure 4A). Furthermore, when we over-expressed SNORD90 we observed an  
206 increase in association of SNORD90 with RBM15B, compared to over-expression of a  
207 scrambled control (figure 4B). We did not observe an increase of SNORD90 association with  
208 Fibrillarin following SNORD90 OE, indicating that SNORD90 showed preference for  
209 interacting with RBM15B (figure 4B). Since snoRNAs and RBM15B are both found in the  
210 nucleus this may in part explain SNORD90's role in interacting with intronic regions of NRG3  
211 pre-mRNA (21, 24). Canonical snoRNAs function by guiding their partner proteins to target  
212 transcripts which, in-turn, induce a chemical modification (27). Thus, we hypothesized that  
213 SNORD90 is likely acting as a guide RNA for RBM15B and its associated m6A writer complex,  
214 resulting in an increase in m6A levels on NRG3. To test this hypothesis, we measured total m6A  
215 abundance on NRG3 and pre-NRG3 transcripts from our SNORD90 OE in-vitro NPC culture  
216 experiments detailed above. We observed an increase of m6A abundance on both NRG3 and pre-  
217 NRG3, following SNORD90 OE, whereas seed scramble OE and full scramble OE did not alter  
218 m6A abundance (figure 4C-D). Furthermore, introducing target blockers blunted the increase of  
219 m6A abundance on both NRG3 and pre-NRG3 (figure 4E-F). To further test RBM15B's role in  
220 the observed increase in m6A levels on NRG3, we used dicer-substrate short interfering RNAs  
221 (dsiRNAs) to knock-down RBM15B (RBM15B KD) (supplementary figure 6). RBM15B KD

222 followed by SNORD90 OE blunted the increase of m6A levels on NRG3 and pre-NRG3 (figure  
223 4G-H). RBM15B KD also blunted the decrease of NRG3 expression following SNORD90 OE  
224 (figure 4G-H). Interestingly we observed a significant negative correlation between m6A levels  
225 and expression of NRG3, but this was not observed for pre-NRG3, which could possibly be  
226 explained by the fact that m6A-readers are primarily located in the cytoplasm, and thus would  
227 only recognize the m6A-modifications of the mature NRG3 transcript and promote its decay  
228 when it is shuttled out of the nucleus into the cytoplasm (supplementary figure 7). Ke et al., 2017  
229 demonstrated that m6A modifications are added onto nascent pre-mRNA during transcription  
230 (28). Moreover, m6A levels remain unchanged between nascent pre-mRNA and steady-state  
231 mRNA in the cytoplasm (28). Our results further support these findings as it is possible that  
232 SNORD90 is guiding m6A modifications onto NRG3 at the pre-mRNA level, which are retained  
233 in the mRNA molecule. Although it is unclear why SNORD90 targets intronic regions, while it  
234 seems that m6A modifications are deposited onto exonic regions, this could perhaps be explained  
235 by the secondary structure of the RNA molecule where exonic regions could be looping closer to  
236 the SNORD90-guided methylation complex.

237

238 The YTH family of proteins are the best described readers of RNA m6A modifications. The  
239 YTH family includes: YTHDF1, YTHDF2, YTHDF3, YTHDC1, and YTHDC2. Of these,  
240 YTHDF1, YTHDF2 and YTHDF3 regulate RNA stability, whereas functional implications for  
241 YTHDC1 and YTHDC2 are less well defined (29, 30). Furthermore, YTHDF1, YTHDF2,  
242 YTHDF3, and YTHDC2 are primarily located in the cytoplasm, whereas YTHDC1 is primarily  
243 located in the nucleus (31). We selectively knocked-down each of the above-mentioned m6A-  
244 readers using dsRNAs followed by SNORD90 OE to elucidate which m6a-reader(s) are

245 involved in the down-regulation of NRG3 (figure 4I & supplementary figure 8). Although  
246 YTHDF1 KD, YTHDF2 KD, and YTHDF3 KD all showed the ability to blunt the decreased  
247 NRG3 expression following SNORD90 OE, YTHDF2 displayed the most robust ability to blunt  
248 this effect, recovering NRG3 expression to WT patterns (figure 4I). On the other hand, YTHDC2  
249 KD and YTHDC1 KD did not blunt the decrease of NRG3 expression after SNORD90 OE;  
250 displaying similar patterns of NRG3 expression to SNORD90 OE with a dsRNA scramble  
251 control (siControl) (figure 4I). Interestingly, YTHDC1 KD, the nuclear m6a-reader, resulted in a  
252 decrease of pre-mRNA levels of NRG3 expression compared to WT, while knock-down of all  
253 other m6a-readers had no significant effect on pre-NRG3 expression levels (supplementary  
254 figure 9). Together this evidence supports the hypothesis that 1) SNORD90 increases NRG3  
255 m6A transcript methylation and subsequent decay, and 2) that the decay occurs primarily in the  
256 cytoplasm (figure 4J). This, in turn, explains why we only observed changes in NRG3 mRNA  
257 and protein levels, but did not observe changes in pre-mRNA levels following SNORD90 OE.

258

### 259 **SNORD90 mediates down-regulation of Nrg3 resulting in increased glutamatergic** 260 **neurotransmission**

261 We next investigated the functional relevance of decreased NRG3 expression in-vivo. NRG3 has  
262 previously been shown to interact with syntaxin, disrupting SNARE complex formation in the  
263 presynaptic terminal, and inhibiting vesicle docking (19). Nrg3 knock-out resulted in increased  
264 probability of glutamate release in mouse hippocampal neurons (19). To investigate if  
265 SNORD90-mediated down-regulation of NRG3 has a similar effect in mice, we first investigated  
266 if SNORD90's ability to down-regulate NRG3 is conserved in mice. We performed in-silico  
267 target prediction between mouse Snord90 and Nrg3 using "PLEXY" (supplementary table 7).

268 Although predicted sequence complementary sites between Snord90 and Nrg3 are not as robust  
269 as in humans, there is conservation between the two species (supplementary table 7 and  
270 supplementary figure 10). To further explore this effect, we over-expressed Snord90 or a full  
271 scrambled control in the mouse ACC (cg1/2) via bilateral injections of an AAV virus (figure  
272 5A). RT-qPCR confirmed successful over-expression of Snord90 and subsequent down-  
273 regulation of Nrg3 in mice (figure 5B). Next, we performed whole-cell patch-clamp recordings  
274 from pyramidal neurons of the ACC in acute brain slices from mice over-expressing Snord90 or  
275 the full scramble control. We observed an increase in spontaneous excitatory postsynaptic  
276 currents (sEPSC) frequency following Snord90 OE compared to full scramble control without  
277 any effect on sEPSC amplitude (figure 5C-E). This increase in glutamatergic neurotransmission  
278 is likely due to an increase in glutamate release probably resulting from NRG3 pre-synaptic  
279 expression and effect on SNARE complex (19). Together this indicates that SNORD90-mediated  
280 down-regulation of NRG3 has implications in glutamate neurotransmission, which translates to  
281 behavioral changes such as anxiolytic and anti-depressive-like behaviors.

282

## 283 **DISCUSSION:**

284 In this study, we demonstrated that SNORD90 mediates antidepressant drug action through  
285 regulation of NRG3. While it is unclear how serotonergic antidepressant drugs may promote the  
286 increase of SNORD90 expression, one possible mechanism may be through histone  
287 serotonylation. Previous studies have demonstrated that serotonin can covalently attach to  
288 histone H3 and influence gene expression (32). The administration of serotonergic  
289 antidepressants could change intracellular monoamine levels influencing the expression of  
290 SNORD90; however, future studies are needed to investigate this hypothesis. Our results indicate

291 that SNORD90 associates with RBM15B and is involved in mediating m6A modifications,  
292 specifically onto NRG3. This is a slight but significant divergence from canonically functioning  
293 C/D box snoRNAs that are known to associate with fibrillarin, a methyltransferase responsible  
294 for 2'O-methylation (2'OMe) (33, 34). Whereas 2'OMe can occur on the ribose of any base and  
295 is associated with increased RNA stability, m6A is an adenosine specific modification with a  
296 diverse range of effects on RNA stability (31, 35). Specifically, our data show that increased  
297 m6A levels elicit NRG3 decay through recognition by the m6A reader YTHDF2. Furthermore,  
298 SNORD90's influence on NRG3 appears to bridge a relationship between the monoaminergic  
299 and the glutamatergic systems. Many studies have shown that antidepressant drugs target the  
300 monoaminergic system but also affect the glutamatergic system (9). However, it has not been  
301 clear until now what is mediating these effects, though they have often been attributed to off  
302 target binding of antidepressant drugs. Our study offers molecular evidence supporting one  
303 particular mechanism that might mediate the link between serotonin targeting drugs and  
304 activation of the glutamatergic system. Although NRG3 expression has been associated with  
305 psychiatric disorders including MDD, it has not previously been associated with antidepressant  
306 treatment (18). NRG3 is primarily expressed in excitatory pyramidal neurons, and accordingly,  
307 the increase of SNORD90 in response to antidepressant treatment, can yield specific effects on  
308 excitatory glutamatergic neurons and thus glutamatergic neurotransmission (19, 36). Gaining a  
309 better understanding of the molecular mechanisms of antidepressant treatment response will  
310 offer new targets for the development of more effective treatments of MDD.

311

## 312 **MATERIALS AND METHODS:**

### 313 **Human Clinical trial Subjects**

314 Three independent cohorts were used in this study, comprising 660 individuals (37-39).

315

316 Cohort 1 (N=258) was obtained in collaboration with Lundbeck A/S sponsored clinical trials and  
317 is composed of individuals diagnosed with MDD in a current major depressive episode (MDE)  
318 who were enrolled in a double-blind clinical trial and received treatment with either duloxetine  
319 (60mg), a serotonin-norepinephrine reuptake inhibitor (SNRI), or placebo for eight weeks. For  
320 each patient, peripheral blood samples were collected at baseline (T0) and after treatment (T8).  
321 Participants, aged 19–74 years, were recruited based on a primary diagnosis of MDD and MDE  
322 lasting at least 3 months, with a severity score on the Montgomery-Åsberg Depression Rating  
323 Scale (MADRS) of  $\geq 22$  at T0. Participants resistant to at least two previous AD treatments or  
324 who had received electroconvulsive therapy in the 6 weeks before the study began were  
325 excluded. Other exclusion criteria included: MDE in bipolar disorder, presence of psychotic  
326 features, and recent substance use disorder. This clinical trial was approved by ethics boards of  
327 participating centers, and all participants provided written informed consent.

328 [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov) (11984A NCT00635219; 11918A NCT00599911; 13267A

329 NCT01140906). For more details, please refer methods section of Lopez et al., 2017 (37).

330

331 Cohort 2 (N=236) was obtained in collaboration with the Canadian Biomarker Integration  
332 Network in Depression (CAN-BIND) and is composed of individuals diagnosed with MDD  
333 (N=153) and healthy controls (N=83). Patients and controls were recruited at six Canadian  
334 clinical centers. Exclusion criteria included personal and family history of schizophrenia or  
335 bipolar disorder, or current substance dependence. Depressed patients were treated with  
336 escitalopram (10-20mg per day), a selective serotonin reuptake inhibitor (SSRI), for eight weeks.

337 Depression severity was assessed at baseline and after treatment by MADRS. This trial was  
338 approved by ethics boards of participating centers and all participants provided written informed  
339 consent. [www.ClinicalTrials.gov](https://www.ClinicalTrials.gov) identifier NCT01655706. Registered 27 July 2012. For more  
340 details, please refer to Kennedy et al., 2019 (38).

341  
342 Cohort 3 (N=166) was obtained at the Douglas Mental Health University Institute and is  
343 composed of healthy controls (N=28) and individuals diagnosed with MDD (N=138) who were  
344 enrolled in the community outpatient clinic at the Douglas Mental Health University Institute.  
345 Depressed patients were treated with either desvenlafaxine, a serotonin-norepinephrine reuptake  
346 inhibitor (SNRI) or escitalopram, a selective serotonin reuptake inhibitor (SSRI). For each  
347 patient, a blood sample was taken at baseline before treatment administration and 8 weeks post-  
348 treatment. Participants (healthy controls and individuals with MDD) were excluded from the  
349 study if they had comorbidity with other major psychiatric disorders, if they had positive tests for  
350 illicit drugs at any point during the study, or if they had general medical illnesses. Individuals  
351 with MDD were not receiving antidepressant treatment at the onset of the trial, and received a  
352 diagnosis of MDD without psychotic features, according to the Statistical Manual of Mental  
353 Disorders, Fourth Edition (DSM-IV). Control subjects were excluded if they had a history of  
354 antidepressant treatment. Eligible participants were randomized to either desvenlafaxine (50-  
355 100mg) or escitalopram (10-20mg) treatment. All subjects included in the study provided  
356 informed consent, and the project was approved by The Institutional Review Board of the  
357 Douglas Mental Health University Institute. For more details, please refer to Jollant et al., 2020  
358 (39).

359

360 ***Clinical Assessment***

361 All participants from all cohorts were assessed for depression severity after 6 to 8 weeks of  
362 treatment. To quantify treatment response, we calculated percentage change of MADRS scores  
363 (from baseline to after treatment). We used percentage change to correct for the potential effects  
364 of differential baseline scores. Additionally, we classified participants as responder/non-  
365 responder based on >50% decrease in MADRS scores from baseline.

366

367 ***Human peripheral blood sample processing and RNA Extraction***

368 Peripheral blood samples from cohort 1 were collected in PAXgene blood RNA tubes  
369 (PreAnalytix). Total RNA was isolated from whole blood using the PAXgene Blood miRNA Kit  
370 (Qiagen, Canada) according to the manufacturer's instructions. Peripheral blood samples from  
371 cohort 2 and cohort 3 were collected in EDTA blood collection tubes and passed through  
372 LeukoLOCK filters (ThermoFisher) to capture the total leukocyte population, eliminating red  
373 blood cells, platelets, and plasma. Filters, containing leukocytes, were frozen at -80C for storage  
374 until ready for sample processing. Total RNA was extracted using a modified version of the  
375 LeukoLOCK Total RNA Isolation System protocol (ThermoFisher). All samples were treated  
376 with DNase digestion during RNA purification using the RNase-Free DNase kit (Qiagen). RNA  
377 yield and quality were determined using the Nanodrop 1000 (Thermo Scientific, USA) and  
378 Agilent 2200 TapeStation (Agilent Technologies, USA).

379

380 ***Library Construction and Small RNA-Sequencing***

381 Libraries for cohort 1 and cohort 3 were prepared using the Illumina TruSeq Small RNA  
382 protocol following the manufacturer's instructions. Libraries for cohort 2 were prepared using



383 NEB small RNA protocol following manufacturer's instructions. All libraries were purified  
384 using biotinylated magnetic AMPure beads that allow for selection of specified complementary  
385 cDNA products bound to streptavidin. A total of 50µl of amplified cDNA were mixed and  
386 purified twice with AMPure XP beads in a 1.8:1 ratio (beads/sample). Cohort 1 was sequenced  
387 using Illumina HiSeq2500, cohort 2 was sequenced using Illumina HiSeq4000, and cohort 3 was  
388 sequenced using Illumina HiSeq2000. All samples were sequenced at the McGill University and  
389 Genome Quebec Innovation Centre (Montreal, Canada) using 50 nucleotide single-end reads. All  
390 sequencing data was extracted from FASTQ files and processed using CASAVA 1.8+. Illumina  
391 adapter sequences were trimmed using the Fastx\_toolkit, and additionally filtered by applying  
392 the following cut-offs: (1) Phred quality (Q) score higher than 30, (2) reads between 15-40nt in  
393 length, (3) adapter detection based on perfect-10nt match, and (4) removing reads without  
394 detected adapters. Bowtie35 (John Hopkins University) was used to align reads to the human  
395 genome (GRCh37). Furthermore, Rfam database was used to map reads to known small  
396 nucleolar RNAs. Sequencing data was normalized with the Bioconductor-DESeq2 package.

397

### 398 *Statistical analysis*

399 For each subject in these trials, samples collected before administration of an antidepressant (T0)  
400 and eight weeks following antidepressant treatment (T8) were analyzed according to response to  
401 treatment based on MADRS score changes. For the discovery cohort, antidepressant treated, and  
402 placebo treated subjects were analyzed separately.

403

404 A two-way mixed multivariable analysis of variance (2WM-MANOVA) was used to identify  
405 snoRNAs that had a significant interaction between treatment response (response/non-response)

406 and treatment course (T0/T8). For cohort 1, antidepressant treated, and placebo treated subjects  
407 were analyzed separately. All detected snoRNAs were assessed in cohort 1. Only snoRNAs that  
408 showed significant interactions were assessed in cohort 2 and subsequently only snoRNAs that  
409 were replicated in cohort 2 were assessed in cohort 3. For all cohorts, outliers were identified  
410 using boxplot methods with values above quartile 3 (Q3) + 1.5 interquartile range (IQR) or  
411 below quartile 1(Q1) - 1.5IQR (IQR=Q3-Q1). Shapiro-Wilk test and QQ plots were used to  
412 assess data normality. All above mentioned tools were apart of publicly available R package  
413 “rstatix” (<https://CRAN.R-project.org/package=rstatix>) (40).

414

#### 415 **Unpredicted chronic mild stress (UCMS) mouse model:**

416 Eight-week old male BALB/c mice (N=23; Centre d’Elevage Janvier, Le Genest St. Isle, France)  
417 were divided into four groups as described by Herve et al., 2017 (12). In brief, control group (N  
418 = 5) was kept in standard housing conditions for 8 weeks. UCMS only group (N = 7) comprised  
419 of mice subjected to the Unpredictable Chronic Mild Stress (UCMS) procedure for 8 weeks.  
420 UCMS-flx group (N=5) included mice that were subjected to the UCMS procedure for 8 weeks  
421 and treated in parallel by fluoxetine (flx) during the last 6 weeks. Flx only group (N = 6)  
422 included mice that did not undergo the UCMS procedure but were treated with fluoxetine during  
423 the last 6 weeks. Mice from the control and flx only groups were housed in standard cages,  
424 whereas the UCMS-exposed mice were isolated in individual home cages with no physical  
425 contact with other mice. The stressors used were varied and applied in a different sequence each  
426 week to avoid habituation.

427

428 Stressors consisted of housing on damp sawdust (about 200 mL of water for 100 g of sawdust),  
429 sawdust changing (replacement of the soiled sawdust by an equivalent volume of new sawdust),  
430 placement in an empty cage (usually the home cage of the subject, but with no sawdust),  
431 placement in an empty cage with water (the mouse is placed in its empty cage, whose bottom has  
432 been filled up with 1 cm high water at 21°C), switching cages (also sometimes termed as social  
433 stress: the mouse from a cage A is placed in the soiled cage from mouse B, mouse B itself being  
434 absent in order to avoid aggressive interactions), cage tilting (45°), predator sounds, introduction  
435 of rat or cats feces as well as fur in the mouse home cage, inversion of the light/dark cycle, lights  
436 on for a short time during the dark phase or light off during the light phase, confinement in small  
437 tubes (diameter: 4 cm; length: 5 cm).

438

#### 439 ***Mice Behavior***

440 Weight and coat state were measured weekly, as markers of UCMS-induced depressive-like  
441 behavior, except for the last week before sacrifice, when coat state from seven different areas of  
442 the body was recorded twice, separated by 3-day intervals. At the end of the 8th week, a  
443 complementary test of nest building was performed just before sacrifice. The test was  
444 administered by isolating mice in their home cages. For additional details please refer to Herve et  
445 al., 2017 (12).

446

#### 447 ***Quantification and statistical analysis***

448 Details related brain dissection and RNA extraction can be found at Herve et al., 2017 (12). RNA  
449 was reverse-transcribed using M-MLV Reverse Transcriptase (200 U/μL) (ThermoFisher) with  
450 random hexamers. SNORD90 and NRG3 were quantified by RT-PCR using SYBR green

451 (Applied Biosystems). Reactions were run in triplicate using the QuantStudio 6 Flex System and  
452 data collected using QuantStudio Real-Time PCR Software v1.3. One-way ANOVA was used as  
453 described above.

454

#### 455 **Human Post-Mortem Brain**

456 Post-mortem samples of dorsal ACC (Brodmann Area 24) were obtained, in collaboration with  
457 the Quebec Coroner's Office, from the Douglas-Bell Canada Brain Bank (Douglas Mental  
458 Health University Institute, Montreal, Quebec, Canada). Groups were matched for post-mortem  
459 interval (PMI), pH and age. Psychological autopsies were performed as described previously,  
460 based on DSM-IV criteria (41). The control group had no history of major psychiatric disorders.  
461 All cases met criteria for MDD or depressive disorder not-otherwise-specified. Written informed  
462 consent was obtained from next-of-kin. This study was approved by the Douglas Hospital  
463 Research Centre institutional review board.

464

#### 465 ***RNA-sequencing***

466 RNA was extracted from all brain samples using a combination of the miRNeasy Mini kit and  
467 the RNeasy MinElute Cleanup kit (Qiagen), with DNase treatment, and divided into small  
468 (<200 nt) and large (>200 nt) fractions. RNA quality, represented as RNA Integrity Number, was  
469 assessed using the Agilent 2200 TapeStation. Small RNA-seq libraries were prepared from the  
470 small RNA fraction, using the Illumina TruSeq Small RNA protocol following the  
471 manufacturer's instructions. Samples were sequenced at the McGill University and Genome  
472 Quebec Innovation Centre (Montreal, Canada) using the Illumina HiSeq2000 with 50nt single-  
473 end reads. All sequencing data were processed using CASAVA 1.8 + (Illumina) and extracted

474 from FASTQ files. The Fastx\_toolkit was used to trim the Illumina adapter sequences.  
475 Additional filtering based on defined cutoffs was applied, including: (1) Phred quality (Q) mean  
476 scores higher than 30, (2) reads between 15 and 40 nt in length, (3) adapter detection based on  
477 perfect-10nt match, and (4) removal of reads without detected adapter. In addition, we used  
478 Bowtie [24] to align reads to the human genome (GRCh37). Furthermore, all sequencing data  
479 was normalized with the Bioconductor—DESeq2 package, using a detection threshold of 10  
480 counts per snoRNA. We retained all snoRNAs with >10 reads in 70% of either group (controls,  
481 cases) for differential analyses. RNA extractions, sequencing, and data processing were  
482 conducted by blinded investigators. For additional details please refer to Fiori et al., 2020 (42).  
483

#### 484 *Statistical analysis*

485 Using toxicology screens, each sample was separated into the following groups: MDD with  
486 presence of antidepressants, MDD with presence of non-antidepressant drugs, MDD with  
487 negative toxicology screen, controls with non-antidepressant drugs, and controls with negative  
488 toxicology screens. No control samples were positive for antidepressant drugs. For this analysis  
489 we only investigated the expression for SNORD90 from this small RNA sequencing dataset.  
490 NRG3 was measured via qPCR from cDNA converted from the same RNA aliquot for each  
491 sample. Analysis was performed in R using “rstatix” as mentioned above employing a one-way  
492 ANOVA. Shapiro-Wilk test and QQ plots were used to assess data normality.

493

#### 494 **Human hindbrain NPC Culture and neuronal differentiation**

495 Monoamine producing neurons were generated from human induced pluripotent stem cells  
496 (iPSCs), using a protocol adapted from Lu et al. 2016 (43). Human iPSCs were first cultured in

497 DMEM/F12 (Gibco) supplemented with N2 (Gibco), B27 (Gibco), nonessential amino acids  
498 (Gibco), 1% GlutaMAX (Gibco), 2 uM SB431542 (STEMCELL Tech.), 2uM DMH1 (Tocris),  
499 and 3uM CHIR99021 (Tocris); collectively referred to as SDC media. Culturing in SDC media  
500 for 1 week induces human iPSC differentiation into rostral hindbrain neural stem cells (NSCs).  
501 Rostral hindbrain NSCs colonies were selected and re-plated in SDC media supplemented with  
502 1000 ng/ml of SHH C25II (GenScript). Hindbrain NPCs were GBX2, HOXA2, and HOXA4  
503 positive as assessed via quantitative RT-PCR to confirm hindbrain specificity at this  
504 developmental stage. Ventral rostral hindbrain NSC colonies were collected and re-plated in  
505 SDC + SHH media along with 10ng/ml of FGF4 (PeproTech). SDC + SHH + FGF4 media will  
506 induce ventral rostral hindbrain NSC differentiation into neural progenitor cells (NPCs) after 1  
507 week. NPCs were expanded in SDC+SHH+FGF4 media and differentiated into monoamine  
508 producing neuron-like cells. NPCs were differentiated, for 1 month, into neuron-like cells in  
509 neurobasal media (Gibco) supplemented with N2, B27, NEAA, 1ug/ml laminin (Sigma), 0.2mM  
510 vitamin C (Sigma), 2.5uM DAPT (Sigma), 10ng/ml GDNF (GenScript), 10ng/ml BDNF  
511 (GenScript), 10ng/ml insulin-like growth factor-I (Pepro Tech), and 1ng/ml transforming growth  
512 factor  $\beta$ 3 (Pepro Tech). Post-differentiation, neuron-like cells underwent high-performance  
513 liquid chromatography (HPLC) to test for monoamine production. HPLC confirmed production  
514 of norepinephrine (NE), epinephrine (epi), dopamine (DA), and serotonin (5-HT). All NPCs and  
515 differentiated NPCs were seeded on culture plates coated with 100ug/mL poly-L-ornithine  
516 (sigma) and 10ug/mL laminin (Sigma) and grown in a 5% CO<sub>2</sub> humidified incubator at 37°C.

517

518 ***High Performance Liquid Chromatography***

519 Cells were sonicated in 60uL of 0.25 N perchloric acid. Protein and cellular debris were cleared  
520 by centrifugation at 11,000g at 4°C for 10 min. Pellets were re-suspended in 100µl of 0.1N  
521 NaOH. 20uL of tissue homogenates, cleared of protein and debris, was injected using a  
522 refrigerated ultiMate 3000 rapid separation autosampler (ThermoFisher) into a HPLC system  
523 consisting of a luna 3 u C18 (2) 100 A 75 X 4.6 mm phenomemex and a coulometric  
524 electrochemical detector (ThermoFisher) to quantify monoamines. Oxidation and reduction  
525 electrode potentials of the analytical cell (5014B; ThermoFisher) were set to +300 and -250 mV  
526 respectively. The mobile phase consisting of 73.4mM sodium acetate trihydrate, 66.6mM of  
527 citric acid monohydrate, 0.025mM Na<sub>2</sub>EDTA, 0.341mM 1-octanesulfonic acid, 0.71mM of  
528 Triethylamine and 6% (v/v) methanol (pH adjusted to 4.0-4.1 with acetic acid) was pumped at  
529 1.5 ml/min by a solvent delivery module (dionex ultimat 3000 rs pump).

530

### 531 **NPC Drug Treatment**

532 Human NPCs were screened for cytotoxic effects using the MTT assay, and antidepressants were  
533 applied at nontoxic concentrations as described by Lopez et al., 2014 (44). NPCs were cultured  
534 in 24 well plates and differentiated, for 2 weeks, into neuron-like cells in neurobasal media  
535 (Gibco) supplemented with N2, B27, NEAA, 1 µg/ml laminin (Sigma), 0.2 mM vitamin C  
536 (Sigma), 2.5 µM DAPT (Sigma), 10 ng/ml GDNF (GenScript), 10 ng/ml BDNF (GenScript),  
537 10 ng/ml insulin-like growth factor-I (Pepro Tech), and 1 ng/ml transforming growth factor β3  
538 (Pepro Tech). Following 2 weeks of differentiation, culture media was supplemented with  
539 escitalopram (Sigma-Aldrich, E4786; 100 µM), duloxetine (Sigma-Aldrich, Y0001453; 10 µM),  
540 haloperidol (Sigma-Aldrich, H1512; 10 µM), lithium (Sigma-Aldrich, L4408; 1 mM), Aspirin  
541 (Sigma-Aldrich, A5376; 1mM), or left untreated (controls). Cells for each drug treatment were

542 incubated for 48 h before harvest and RNA extractions. Each drug treatment was performed in  
543 triplicate. RNA was extracted using the Zymo DirectZol RNA Extraction kit. cDNA construction  
544 and RT-qPCR were as described above. One-way ANOVA analysis was performed in IBM  
545 SPSS Statistics version 27 using Dunnett's post-hoc correction.

546

#### 547 **SNORD90 over-expression in mice:**

548 Male CD-1 (ICR) were housed in temperature-controlled ( $23 \pm 1^\circ\text{C}$ ), constant humidity ( $55 \pm$   
549  $10\%$ ), 12-hour light/dark cycle and in specific-pathogen-free conditions. Animals had access to  
550 food and water *ad libidum*. Animals were housed in groups of four. All animal experiments were  
551 evaluated and approved by the local commission for the Care and Use of Laboratory Animals of  
552 the Government of Upper Bavaria, Germany.

553

#### 554 ***Cloning***

555 The Snord90 sequence was obtained from the Ensembl genome browser database (Ensemble ID  
556 ENSMUSG00000077756). The control sequence was generated by scrambling the Snord90 gene  
557 using siRNA wizard software (Invitrogen). Each fragment was designed to have KpnI and  
558 BamHI and a 10-nucleotide long overhang with the vector backbone at the 5' and 3' ends  
559 respectively. Each gene fragment was inserted into a KpnI with BamHI linearized pAAV-EF1a-  
560 eGFP-H1 backbone using Gibson Assembly (NEB) according to the manufacturer's protocol.  
561 This generated the following two vectors, pAAV-EF1a-eGFP-H1-Scramble and pAAV-EF1a-  
562 eGFP-H1-Snord90. All plasmids were checked for mutations by DNA sequencing.

563

564 SNORD90 sequence (mouse):



565 5'AAATAATGTTTTTAAGTGTCTAGTGATGAATTCATAGGGCAGATTCTGAGGTGAA  
566 AATTTAGTTCATCATTGATTGTCCTATTATGAAATCTGAAGACACTTGAAAATA 3'

567

568 Scrambled sequence (mouse):

569 5'GATATTATAACGATTGTTGTATAATCTATTAGAGTGTATCGTAGGCAATGGCTATA  
570 TGTAATGTAACGTATTGTACTCGTATGATTAATTACATAATACGAATACGCTAG 3'

571

### 572 *Validation of constructs*

573 Mouse neuroblastoma neuro2a (N2a) cells were maintained at 37°C with 5% CO<sub>2</sub> in Minimum  
574 Essential Medium (MEM), 1x Glutamax, supplemented with 1x non-essential amino acids, 1mM  
575 sodium pyruvate, 100 U/ml penicillin, 100 µg/ml streptomycin and 10% fetal bovine serum  
576 (FBS, Gibco). Cells were detached with trypsin and transfected using ScreenfectA (ScreenFect  
577 GmbH) according to the manufacturer's protocol. Cells were fixed with 4% PFA-PBS solution  
578 and embedded with Fluoromount-G mounting medium containing DAPI (SouthernBiotech).  
579 Cells were imaged using an Axioplan 2 fluorescent microscope (Zeiss).

580

### 581 *Virus production*

582 Human embryonic kidney cells (HEK293) were cultured in Dulbecco's Modified Eagle Medium  
583 (DMEM) supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin  
584 (Invitrogen) in a 5% CO<sub>2</sub> humidified incubator at 37°C. Cells were transfected with the gene  
585 transfer rAAV plasmid combined with the helper plasmids in an equal molar ratio of 1:1:1 using  
586 1 mg/ml linear polyethylenimine hydrochloride (PEI). The rAAV (serotype 1/2) particles were  
587 harvested three days after transfection by lysing the cells with three consecutive freeze-and-thaw

588 cycles using an ethanol on dry ice bath and 37°C water bath. Lysates were centrifuged (3000 rcf)  
589 followed by purification of the rAAV particles using a Heparin Agarose Type I chromatography  
590 column (Sigma). The eluted rAAV particles were PBS washed using a 100000 MWCO Amicon  
591 Ultra Filter (Millipore) and suspended in a final volume of 100µl. The number of viral genomic  
592 particles was determined using quantitative RT-PCR resulting in the following titers; AAV1/2-  
593 EF1a-eGFP-H1-Scramble  $1,67 \times 10^{11}$  genome particles (gp)/µl and AAV1/2-EF1a-eGFP-H1-  
594 Scramble  $5 \times 10^{10}$  gp/µl.

595

### 596 *Stereotactic surgery*

597 Eight-week-old mice were anesthetized with isoflurane and placed in the stereotactic apparatus  
598 (TSE Systems) on a 37°C heating pad. Pre-surgery, mice were given Novalgine (200 mg/kg body  
599 weight) and Metacam (sub-cutaneous 0.5 mg/kg body weight). During surgery, mice were  
600 continuously supplied with 2% v/v isoflurane in O<sub>2</sub> through inhalation. Viruses were injected  
601 bilaterally using a 33-gauge injection needle with a 5 µl Hamilton syringe coupled to an  
602 automated microinjection pump (World Precision Instruments). Virus was delivered at a rate of  
603 0.1 µl/min, to inject 0.25 µl for behavior experiments, and 0.5 µl for molecular experiments. The  
604 injection coordinates were determined using the Franklin and Paxinos mouse brain atlas, from  
605 bregma: ML +/-0.3 mm bilateral; AP +1.2 mm; DV -1.8 mm. After injection the needle was  
606 retracted 0.01 mm and kept at the site for 2.5 minutes, followed by slow withdrawal. In all  
607 experiments, each group consisted of two scramble control virus injected and two Snord90  
608 overexpression virus injected animals. After surgery, the animals received Metacam for the 3  
609 following days (intraperitoneal 0.5 mg/kg body weight). In all experiments, mice were tested or  
610 tissue was extracted 3-4 weeks after surgery. After completion of the experiments, mice were

611 sacrificed by isoflurane overdose. For imaging of brain material, the brains were removed and  
612 fixed in 4% PFA-PBS followed by dehydration in 30% sucrose-PBS solution for at least 24  
613 hours each. Brains were sectioned (50  $\mu$ m) using a vibratome (HM 650 V, Thermo Scientific).  
614 Brain slices were imaged using the VS120-S6-W slide scanner microscope (Olympus). Injection  
615 sites were verified based on green fluorescent protein (GFP) expression. For RNA extraction, the  
616 brains were extracted and snap-frozen using methylbutane. Brains were sectioned in 200  $\mu$ m  
617 thick slices in a cryostat and the injection site was collected using 0.8 mm thick puncher. The  
618 tissue was stored at -80°C until RNA extraction.

619

#### 620 ***Real-time PCR (RT-PCR)***

621 Total RNA was extracted from cells or tissue using the miRNeasy Mini Kit (Qiagen). cDNA was  
622 generated using the high-capacity cDNA RT kit with RNase inhibitor (Applied Biosystems)  
623 according to the supplied protocol. RT-PCR was performed according to the manufacturer's  
624 instructions using the QuantiFast SYBR green PCR Kit (Qiagen). RT-PCR data was collected on  
625 the QuantStudio 7 Flex Real-Time PCR System (Applied Biosystems). Absolute expression  
626 differences were calculated using the standard curve method. See supplementary table 8 for a list  
627 of primer sequences used.

628

#### 629 ***Behavioral tests***

630 For all behavioral tests, animals were brought into the room 30 minutes prior to the start of the  
631 test to habituate the animals to the test room.

632

633 Open field (OF) test: The OF test was performed in a 50 x 50 cm light grey box, evenly  
634 illuminated with low light conditions (<10 lux). Mice were placed in the open field facing one of  
635 the walls and recorded for 6 minutes. Animals were tracked using ANY-maze software  
636 (Stoelting). Total distance traveled was used as measure of animal locomotion.

637

638 Elevated plus maze (EPM): EPM apparatus was made of light grey material, and consists of four  
639 intersecting arms elevated approximately 30 cm above the floor. The two opposing open (27.5 x  
640 5 cm) and closed arms (27.5 x 5 x 20 cm) are connected with a central zone (5 x 5 cm). The  
641 animals were placed in the center of the EPM, facing one of the open arms and recorded for 6  
642 minutes. The closed arms were illuminated with <10 lux, while the open arms were illuminated  
643 with 25-30 lux. Recordings were tracked and analyzed with ANYmaze software. Total time  
644 spent in the open or closed arms was used as an anxiety measure.

645

646 Splash test (Spl): Animals were placed in a novel cage containing fresh bedding material and  
647 were allowed to explore for 5 minutes. Each animal received two sprays of room temperature  
648 10% sucrose water at the rear of their body. Animals were recorded for 6 minutes under low-  
649 light conditions (<10 lux). The total groom time within the 3-6 minute timeframe was manually  
650 scored using Solomon Coder software.

651

652 Tail suspension test (TST): In the TST, animals were taped by their tails on a metal rod,  
653 approximately 30 cm above the ground, and illuminated with 30-35 lux. Animals were recorded  
654 for 6 minutes and struggle time was quantified using ANY-maze software. The total time an

655 animal struggled within the 3-6 minute timeframe was used as a measure of a depression-like  
656 emotional state.

657  
658 Z-scoring was used to integrate multiple behavioral tests as previously described (45). First, the  
659 z-score of each individual behavioral parameter was calculated.

660

$$z = \frac{X - \mu}{\sigma}$$

661  
662 The z-scores of the EPM open arm, EPM closed arm, Spl and TST were combined to calculate  
663 an integrated emotionality score.

664

$$Emotion\ z\ score = \frac{Z_{EPM} + Z_{Spl} + Z_{TST}}{Number\ of\ tests}$$

665  
666 The final integrated score is associated with anxiety and depressive-like behaviors with a higher  
667 score indicating a higher emotional state, while a lower score indicating a lower emotional state.

668

### 669 **Target Prediction**

670 The entire sequence of SNORD90 was used to blast against the human genome allowing G-T  
671 wobble base pairing and one mismatch base pairing (supplemental table 4). Additionally, the  
672 C/D box snoRNA target prediction algorithm PLEXY, using default parameters, was used for  
673 target prediction of SNORD90 (17). SNORD90 mature sequence was used as the input snoRNA  
674 and target sequence input was the entire human transcriptome using both mRNA and pre-mRNA

675 sequences downloaded from the Ensembl genome browser database (supplementary table 5).

676 Prediction was conducted using whole transcriptomics as well as a targeted analysis for NRG3.

677

### 678 **SNORD90 in-vitro knock-down**

679 SNORD90 was knocked down using antisense oligonucleotides (ASO) containing 2'-O-

680 methylations and phosphorothioate-modified nucleotides (supplementary table 9). Four ASOs

681 and one scrambled control ASO were screened to identify which achieved the best knock-down

682 of SNORD90 (supplementary figure 4). NPCs were plated in 24-well plates until ~90%

683 confluent before transfection with ASO (50nM final concentration) using Lipofectamine 2000

684 (ThermoFisher) following manufacturer's protocol. NPCs were incubated for 48 hours before

685 harvesting for RNA extraction. RNA extraction, cDNA synthesis, and RT-qPCR were as

686 described above. One-way ANOVA was used as described above

687

### 688 **SNORD90 in-vitro over-expression**

689 Constructs and cloning were as described above with the following sequences:

690 SNORD90 sequence:

691 5'TTATAAGTTTTCTAAGTGTCTAATGATGAATTCATAGGGCAGATTCTGAGGTGAA

692 AATTTAATTCATCACTGATACTCCTACTGTGGAATCTGAAGACACTTGAAAACGT 3'

693

694 Seed Scrambled sequence:

695 5'TTATAAGTTTTCTAAGTGTCTAATGATGAATTCATAGGGCAGATTCTGAAATAAT

696 ACTTCGCTTAAGATATTCGACTCCTACTGTGGAATCTGAAGACACTTGAAAACGT 3'

697

698 Scrambled sequence:

699 5'GATTCATAATGAGTTGATTTAATCACATGCTGGCTCTCATTTCGACCAGAATTTCTCT  
700 AGTTGATAAAAAGTAAACCAATGAATTAGTATGTTTGATCAAGATGTATGACTCG 3'

701

702 NPCs were plated in 24-well plates until ~90% confluent before being transfected with each  
703 vector using Lipofectamine 2000 (ThermoFisher) following manufacturer's protocol. NPCs were  
704 incubated for 48 hours before harvesting for RNA extraction. RNA extraction, cDNA synthesis,  
705 and RT-qPCR were as described above. One-way ANOVA was used as described above.

706

### 707 ***Target Blockers***

708 Modified RNA oligos containing 2'-O-methylations and phosphorothioate-modified nucleotides  
709 (target blockers) were designed against three regions on the NRG3 transcript where SNORD90 is  
710 predicted to bind (Figure 3A). Target blockers were co-transfected (30nM final concentration)  
711 with SNORD90 OE vectors using lipofectamine 2000 following manufacturer recommendations  
712 for "plasmid DNA and siRNA" co-transfection. For groups where target blockers were pooled  
713 together, equal amounts for each target blocker were used totaling 30nM final concentration.  
714 NPC culture conditions, RNA extraction, cDNA synthesis, and RT-qPCR were as described  
715 above. One-way ANOVA was used as described above.

716

### 717 **Western blot**

718 Cell pellets from cell culture were lysed in lysis buffer [150 mM NaCl, 50 mM HEPES (pH 7),  
719 50 mM EDTA, and 0.1% NP-40] and quantified using Pierce<sup>TM</sup> BCA Protein Assay Kit (Thermo  
720 Fisher). Equal amounts of proteins were electrophoresed on 4-20% Mini-PROTEAN TGX Stain-

721 Free Gels (Bio Rad). Proteins were then transferred onto nitrocellulose membranes using the  
722 Trans-Blot Turbo Transfer System (Bio Rad). The membranes were blocked with 5% Bovine  
723 Serum Albumin (BSA) in Phosphate-Buffered Saline (0.05% Tween 20) (PBS-T) at room  
724 temperature for 1-2 hrs and then incubated with primary antibody (NRG3 (ab109256) at 1:500  
725 and GAPDH (3683S) at 1:1000) in 1% BSA in PBS-T overnight at 4 °C. They were then  
726 incubated with either biotin-conjugated anti-rabbit antibody (BA-1000) or with Horseradish  
727 Peroxidase (HRP)-conjugated anti-rabbit antibody diluted 1:5000 in 1% BSA in PBS-T for 1 hr  
728 at room temperature. The membranes that were incubated with biotin-conjugated anti-rabbit  
729 antibody were washed with PBS-T and incubated with streptavidin-conjugated HRP (016-030-  
730 084) at 1:5000 in 1% NFDM in PBS-T for 1 hr at room temperature. After washing,  
731 immunoreactivity was detected using enhanced chemiluminescence solutions (ECL) and the  
732 Biorad ChemiDoc<sup>TM</sup> MP imaging system. Western blots were performed in 3 biological  
733 replicates.

734

### 735 **RNA immunoprecipitation**

736 Overexpression of SNORD90 and scramble were performed as described above. RNA  
737 immunoprecipitation (RIP) was performed using the Magna RIP RNA-Binding Protein  
738 Immunoprecipitation kit (Millipore Sigma) following the manufacturer's protocol with slight  
739 modifications. NPCs were collected and lysed in complete RIP lysis buffer. 10 uL of cell extract  
740 was stored at -80°C and used as input. NPC extracts were incubated in RIP buffer containing  
741 magnetic beads conjugated to anti-fibrillarin antibody (ab226178; abcam), anti-RBM15B  
742 antibody (22249-1-AP; proteintech), or IgG control (provided by the kit) overnight in 4°C. Bead  
743 complexes were washed 6 times with RIP buffer and eluted directly in TRIzol. RNA from all



744 conditions were purified in parallel using the RNA microPrep kit (Zymol) and eluted into 15  $\mu$ L  
745 H<sub>2</sub>O. The entire eluate was transcribed to cDNA using M-MLV Reverse Transcriptase  
746 (200 U/ $\mu$ L) (ThermoFisher) with random hexamers. RT-qPCR was as described above.

747

#### 748 **m6A-RIP**

749 m6A-RIP protocol was as described by Engel et al., with minor modifications. 3  $\mu$ g total RNA  
750 was mixed with 3 fmol spike-in and equally split into 3 conditions: m6A-RIP, IgG control and  
751 input. Input samples were frozen and kept at -80C during the m6A-RIP protocol. m6A-RIP and  
752 IgG control samples were incubated with 1  $\mu$ g anti-m6A antibody (rabbit polyclonal 202 003,  
753 Synaptic Systems) or 1  $\mu$ g normal rabbit IgG (NEB) in immunoprecipitation (IP) buffer (10 mM  
754 Tris-HCl [pH 7.5], 150 mM NaCl, 0.1% IGEPAL CA-630 in nuclease-free H<sub>2</sub>O, 0.5 mL total  
755 volume) with 1  $\mu$ L RNasin Plus (Promega) rotating head over tail at 4°C for 2 hrs, followed by  
756 incubation with 2x washed 25  $\mu$ L Dynabeads M-280 (Sheep anti-Rabbit IgG Thermo Fisher  
757 Scientific) rotating head over tail at 4°C for 2 hrs. Bead-bound antibody-RNA complexes were  
758 recovered on a magnetic stand and washed in the following order: twice with IP buffer, twice  
759 with high-salt buffer (10 mM Tris-HCl [pH 7.5], 500 mM NaCl, 0.1% IGEPAL CA-630 in  
760 nuclease-free H<sub>2</sub>O), and twice with IP buffer. RNA was eluted directly into TRIzol and input  
761 RNA was also taken up in TRIzol. RNA from all conditions was purified in parallel using the  
762 RNA microPrep (Zymol) and eluted into 15  $\mu$ L H<sub>2</sub>O. The entire eluate was transcribed to cDNA  
763 using M-MLV Reverse Transcriptase (200 U/ $\mu$ L) (ThermoFisher) with random hexamers. RT-  
764 qPCR was as described above. One-way ANOVA was used as described above

765

#### 766 ***Spike-in***

767 A spike-in Oligo was used as a normalizer for quantitative RT-PCR. The spike-in oligo was  
768 100nt in length with 3 internal m6A/m sites within GGAC motif flanked by the most frequent  
769 nucleotides 5' U/A, 3' A/U, not complementary to hsa or mmu RefSeq mRNA or genome,  
770 secondary structure exposing m6A sites (as described by Engel et al., 2018). The sequence is:  
771 GCAGAACCUAGUAGCGUGUGGmACACGAACAGGUAUCAUAUGCGGGUAUGGmA  
772 CAAAAGCAACGUGCGAGAUUACGCUGAGGmACUACAAUCUCAGUUACCA  
773 (synthesized by Horizon Discoveries).

774

### 775 **Dicer-Substrate Short Interfering RNA (dsiRNA) gene silencing**

776 DsiRNAs KD was assessed via RT-qPCR in the final experimental samples (supplementary  
777 figure 8). In each silencing condition, the siRNA sequences were specific to the m6a reader of  
778 interest, as shown by the quantitative RT-PCR data (supplementary figure 8). Cells were seeded  
779 in 24-well plates and grown to ~70% confluency. 50nM siRNA was transfected using  
780 lipofectamine 2000 according to the manufacturer's instructions. A second transfection was  
781 performed 48hrs after the first transfection. Following the second round of dsiRNA transfection,  
782 SNORD90 OE vectors were transfected 48 hours later. NPCs were then collected 48 hours after  
783 the third transfection. DsiRNA sequences and oligos were provided by IDT (supplementary table  
784 10). RNA extraction, cDNA synthesis, and RT-qPCR were as described above. One-way  
785 ANOVA was used as described above

786

### 787 **Electrophysiological Recording**

788 *Brain slices preparation*

789 Mice were stereotactically injected with SNORD90-OE or SNORD90-Scramble viral vector as  
790 described above.

791  
792 3 weeks after the injection, mice received an overdose injection of pentobarbital (100 mg/kg i.p.)  
793 and were perfused with carbogenated (95% O<sub>2</sub>, 5% CO<sub>2</sub>) ice-cold slicing solution containing (in  
794 mM): 2.5 KCl, 11 glucose, 234 sucrose, 26 NaHCO<sub>3</sub>, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 10 MgSO<sub>4</sub>, 2 CaCl<sub>2</sub>; pH  
795 7.4, 340 mOsm. After decapitation, 300 µm coronal slices containing the ACC were prepared in  
796 carbogenated ice-cold slicing solution using a vibratome (Leica VT 1200S) and allowed to  
797 recover for 20 min at 33°C in carbogenated high osmolarity artificial cerebrospinal fluid (high-  
798 Osm aCSF) containing (in mM): 3.2 KCl, 11.8 glucose, 132 NaCl, 27.9 NaHCO<sub>3</sub>, 1.34  
799 NaH<sub>2</sub>PO<sub>4</sub>, 1.07 MgCl<sub>2</sub>, 2.14 CaCl<sub>2</sub>; pH 7.4, 320 mOsm) followed by 40 min incubation at 33°C  
800 in carbogenated aCSF containing (in mM): 3 KCl, 11 glucose, 123 NaCl, 26 NaHCO<sub>3</sub>, 1.25  
801 NaH<sub>2</sub>PO<sub>4</sub>, 1 MgCl<sub>2</sub>, 2 CaCl<sub>2</sub>; pH 7.4, 300 mOsm. Subsequently, slices were kept at room  
802 temperature (RT) in carbogenated aCSF until use.

803  
804 ***Patch-clamp recordings***  
805 Slices were then transferred in the recording chamber and superfused (4-5 mL/min) with  
806 carbogenated aCSF and recordings performed at RT. Pyramidal neurons of the ACC were  
807 visualized with infrared differential interference contrast (DIC) microscopy (BX51W1,  
808 Olympus) and an Andor Neo sCMOS camera (Oxford Instruments, Abingdon, UK). Somatic  
809 whole-cell voltage-clamp recordings from ACC pyramidal neurons (> 1 GΩ seal resistance, -  
810 70 mV holding potential) were performed using a Multiclamp 700B amplifier (Molecular  
811 Devices, San Jose, CA, USA). Data were acquired using pClamp 10.7 on a personal computer

812 connected to the amplifier via a Digidata-1440 interface (sampling rate: 20 kHz; low-pass filter:  
813 8 kHz). Borosilicate glass pipettes (BF100-58-10, Sutter Instrument, Novato, CA, USA) with  
814 resistances 4-6 M $\Omega$  were pulled using a laser micropipette puller (P-2000, Sutter Instrument).  
815 Data obtained with a series resistance > 20 M $\Omega$  or fluctuation more than 20% of the initial values  
816 were discarded.

817  
818 For sEPSCs recording, pyramidal neurons were clamped at -70 mV in the presence of BIM  
819 (20  $\mu$ M) with the pipette solution containing (in mM): 125 Cs-methanesulfonate, 8 NaCl, 10  
820 HEPES, 0.5 EGTA, 4 Mg-ATP, 0.3 Na-GTP, 20 Phosphocreatine and 5 QX-314 (pH 7.2 with  
821 CsOH, 285-290 mOsm).

822  
823 Analysis was performed using ClampFit 10.7 and Easy Electrophysiology V2.2  
824 (<https://www.easyelectrophysiology.com>), and statistical significance assessed with GraphPad  
825 Prism 7.

826  
827 **ACKNOWLEDGMENTS:** GT holds a Canada Research Chair (Tier 1) and is supported by  
828 grants from the Canadian Institute of Health Research (CIHR) (FDN148374, EGM141899,  
829 ENP161427), and by the Fonds de recherche du Québec -Santé (FRQS) through the Quebec  
830 Network on Suicide, Mood Disorders, and Related Disorders. CAN-BIND is an Integrated  
831 Discovery Program carried out in partnership with, and financial support from, the Ontario Brain  
832 Institute, an independent nonprofit corporation, funded partially by the Ontario government. The  
833 opinions, results, and conclusions are those of the authors and no endorsement by the Ontario  
834 Brain Institute is intended or should be inferred. Additional funding is provided by the Canadian

835 Institutes of Health Research (CIHR). All study medications were independently purchased at  
836 wholesale market values. AC is the incumbent of the Vera and John Schwartz Family  
837 Professorial Chair in Neurobiology at the Weizmann Institute and the head of the Max Planck  
838 Society–Weizmann Institute of Science Laboratory for Experimental Neuropsychiatry and  
839 Behavioral Neurogenetics. This work is supported by the German Ministry of Science and  
840 Education (IMADAPT, FKZ: 01KU1901); the Ruhman Family Laboratory for Research in the  
841 Neurobiology of Stress (AC); research support from Bruno and Simone Licht; the Perlman  
842 Family Foundation, founded by Louis L. and Anita M. Perlman (AC); the Adelis Foundation  
843 (AC); and Sonia T. Marschak (AC). JPL holds postdoctoral fellowships from the European  
844 Molecular Biology Organization (EMBO-ALTF 650-2016), Alexander von Humboldt  
845 Foundation, and the Canadian Biomarker Integration Network in Depression (CAN-BIND). J.D.  
846 is the incumbent of the Achar Research Fellow Chair in Electrophysiology.

847

848 **AUTHOR CONTRIBUTIONS:** RL and GT conceptualized the project with input from AC,  
849 JPL AK, and LMF. JPL performed small RNA sequencing from human clinical samples. PB, FF,  
850 BNF, RWL, RM, DJM, SVP, CS, RU, JAF, and SHK participated in the design the sample  
851 acquisition of the human clinical trials. RL and LMF performed small RNA sequencing on  
852 human post-mortem brain samples. CN and NM contributed to the collection of the human-  
853 postmortem samples and molecular analysis. ZA provided bioinformatic support for analysis of  
854 sequencing data. AK performed mouse behavioral experiments. ECI and CB provided mouse  
855 ACC samples. JD performed electrophysiology experiments; YJB performed surgeries with  
856 input from AK and JPL. TPW provided input on electrophysiology experiments. PI performed  
857 western blots. RL performed cell culture experiments with input from JY. RL and HH performed

858 m6A experiments. RL and GT wrote the manuscript with input from AK, JPL, JD, JBF, TPW,  
859 ECI, CB, PB, FF, BNF, RWL, RM, DJM, SVP, CS, RU, CN, NM, JAF, SHK, and AC.

860

861 **COMPETING INTERESTS:** RM has received consulting and speaking honoraria from  
862 AbbVie, Allergan, Eisai, Janssen, KYE, Lallemand, Lundbeck, Neomind, Otsuka, and Sunovion,  
863 and research grants from CAN-BIND, CIHR, Janssen, Lallemand, Lundbeck, Nubiyota, OBI and  
864 OMHF. JAF has received consulting and speaking fees from Takeda and RBH, and research  
865 funding from NSERC, CIHR, and OBI.

866

## 867 REFERENCES:

- 868 1. D. J. Brody, Q. Gu, Antidepressant Use Among Adults: United States, 2015-2018. *NCHS*  
869 *Data Brief*, 1-8 (2020).
- 870 2. A. Cipriani *et al.*, Comparative efficacy and acceptability of 21 antidepressant drugs for  
871 the acute treatment of adults with major depressive disorder: a systematic review and  
872 network meta-analysis. *Lancet* **391**, 1357-1366 (2018).
- 873 3. C. J. Harmer, R. S. Duman, P. J. Cowen, How do antidepressants work? New  
874 perspectives for refining future treatment approaches. *Lancet Psychiatry* **4**, 409-418  
875 (2017).
- 876 4. S. B. Ross, A. L. Renyi, Inhibition of the uptake of tritiated 5-hydroxytryptamine in brain  
877 tissue. *Eur J Pharmacol* **7**, 270-277 (1969).
- 878 5. J. Vetulani, F. Sulser, Action of various antidepressant treatments reduces reactivity of  
879 noradrenergic cyclic AMP-generating system in limbic forebrain. *Nature* **257**, 495-496  
880 (1975).
- 881 6. R. M. Berman *et al.*, Antidepressant effects of ketamine in depressed patients. *Biol*  
882 *Psychiatry* **47**, 351-354 (2000).
- 883 7. R. S. Duman, Ketamine and rapid-acting antidepressants: a new era in the battle against  
884 depression and suicide. *F1000Res* **7**, (2018).
- 885 8. G. Bonanno *et al.*, Chronic antidepressants reduce depolarization-evoked glutamate  
886 release and protein interactions favoring formation of SNARE complex in hippocampus.  
887 *J Neurosci* **25**, 3270-3279 (2005).
- 888 9. L. Musazzi, G. Treccani, A. Mallei, M. Popoli, The action of antidepressants on the  
889 glutamate system: regulation of glutamate release and glutamate receptors. *Biol*  
890 *Psychiatry* **73**, 1180-1188 (2013).
- 891 10. H. S. Mayberg *et al.*, Deep brain stimulation for treatment-resistant depression. *Neuron*  
892 **45**, 651-660 (2005).


- 893 11. M. Roet *et al.*, Deep Brain Stimulation for Treatment-Resistant Depression: Towards a  
894 More Personalized Treatment Approach. *J Clin Med* **9**, (2020).
- 895 12. M. Herve *et al.*, Translational Identification of Transcriptional Signatures of Major  
896 Depression and Antidepressant Response. *Front Mol Neurosci* **10**, 248 (2017).
- 897 13. L. Lestrade, M. J. Weber, snoRNA-LBME-db, a comprehensive database of human  
898 H/ACA and C/D box snoRNAs. *Nucleic Acids Res* **34**, D158-162 (2006).
- 899 14. C. Ender *et al.*, A human snoRNA with microRNA-like functions. *Mol Cell* **32**, 519-528  
900 (2008).
- 901 15. S. Kishore, S. Stamm, The snoRNA HBII-52 regulates alternative splicing of the  
902 serotonin receptor 2C. *Science* **311**, 230-232 (2006).
- 903 16. E. Sharma, T. Sterne-Weiler, D. O'Hanlon, B. J. Blencowe, Global Mapping of Human  
904 RNA-RNA Interactions. *Mol Cell* **62**, 618-626 (2016).
- 905 17. S. Kehr, S. Bartschat, P. F. Stadler, H. Tafer, PLEXY: efficient target prediction for box  
906 C/D snoRNAs. *Bioinformatics* **27**, 279-280 (2011).
- 907 18. C. Paterson *et al.*, Temporal, Diagnostic, and Tissue-Specific Regulation of NRG3  
908 Isoform Expression in Human Brain Development and Affective Disorders. *Am J*  
909 *Psychiatry* **174**, 256-265 (2017).
- 910 19. Y. N. Wang *et al.*, Controlling of glutamate release by neuregulin3 via inhibiting the  
911 assembly of the SNARE complex. *Proc Natl Acad Sci U S A* **115**, 2508-2513 (2018).
- 912 20. D. Zhang *et al.*, Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds  
913 and activates ErbB4. *Proc Natl Acad Sci U S A* **94**, 9562-9567 (1997).
- 914 21. M. Falaleeva *et al.*, Dual function of C/D box small nucleolar RNAs in rRNA  
915 modification and alternative pre-mRNA splicing. *Proc Natl Acad Sci U S A* **113**, E1625-  
916 1634 (2016).
- 917 22. L. P. Benoit Bouvrette, S. Bovaird, M. Blanchette, E. Lecuyer, oRNAmant: a database of  
918 putative RNA binding protein target sites in the transcriptomes of model species. *Nucleic*  
919 *Acids Res* **48**, D166-D173 (2020).
- 920 23. E. L. Van Nostrand *et al.*, A large-scale binding and functional map of human RNA-  
921 binding proteins. *Nature* **583**, 711-719 (2020).
- 922 24. D. P. Patil *et al.*, m(6)A RNA methylation promotes XIST-mediated transcriptional  
923 repression. *Nature* **537**, 369-373 (2016).
- 924 25. D. Tollervey, H. Lehtonen, M. Carmo-Fonseca, E. C. Hurt, The small nucleolar RNP  
925 protein NOP1 (fibrillarin) is required for pre-rRNA processing in yeast. *EMBO J* **10**, 573-  
926 583 (1991).
- 927 26. D. Tollervey, H. Lehtonen, R. Jansen, H. Kern, E. C. Hurt, Temperature-sensitive  
928 mutations demonstrate roles for yeast fibrillarin in pre-rRNA processing, pre-rRNA  
929 methylation, and ribosome assembly. *Cell* **72**, 443-457 (1993).
- 930 27. J. Kufel, P. Grzechnik, Small Nucleolar RNAs Tell a Different Tale. *Trends Genet* **35**,  
931 104-117 (2019).
- 932 28. S. Ke *et al.*, m(6)A mRNA modifications are deposited in nascent pre-mRNA and are not  
933 required for splicing but do specify cytoplasmic turnover. *Genes Dev* **31**, 990-1006  
934 (2017).
- 935 29. K. D. Meyer, S. R. Jaffrey, Rethinking m(6)A Readers, Writers, and Erasers. *Annu Rev*  
936 *Cell Dev Biol* **33**, 319-342 (2017).
- 937 30. S. Zaccara, S. R. Jaffrey, A Unified Model for the Function of YTHDF Proteins in  
938 Regulating m(6)A-Modified mRNA. *Cell* **181**, 1582-1595 e1518 (2020).

- 939 31. S. Zaccara, R. J. Ries, S. R. Jaffrey, Reading, writing and erasing mRNA methylation.  
940 *Nat Rev Mol Cell Biol* **20**, 608-624 (2019).
- 941 32. L. A. Farrelly *et al.*, Histone serotonylation is a permissive modification that enhances  
942 TFIID binding to H3K4me3. *Nature* **567**, 535-539 (2019).
- 943 33. T. Ideue, K. Hino, S. Kitao, T. Yokoi, T. Hirose, Efficient oligonucleotide-mediated  
944 degradation of nuclear noncoding RNAs in mammalian cultured cells. *RNA* **15**, 1578-  
945 1587 (2009).
- 946 34. D. R. Newman, J. F. Kuhn, G. M. Shanab, E. S. Maxwell, Box C/D snoRNA-associated  
947 proteins: two pairs of evolutionarily ancient proteins and possible links to replication and  
948 transcription. *RNA* **6**, 861-879 (2000).
- 949 35. D. G. Dimitrova, L. Teyssset, C. Carre, RNA 2'-O-Methylation (Nm) Modification in  
950 Human Diseases. *Genes (Basel)* **10**, (2019).
- 951 36. G. Bartolini *et al.*, Neuregulin 3 Mediates Cortical Plate Invasion and Laminar Allocation  
952 of GABAergic Interneurons. *Cell Rep* **18**, 1157-1170 (2017).
- 953 37. J. P. Lopez *et al.*, MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of  
954 antidepressant response and regulate MAPK/Wnt-system genes. *Nat Commun* **8**, 15497  
955 (2017).
- 956 38. S. H. Kennedy *et al.*, Symptomatic and Functional Outcomes and Early Prediction of  
957 Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy  
958 in Patients With Major Depressive Disorder: A CAN-BIND-1 Report. *J Clin Psychiatry*  
959 **80**, (2019).
- 960 39. F. Jollant *et al.*, Neural and molecular correlates of psychological pain during major  
961 depression, and its link with suicidal ideas. *Prog Neuropsychopharmacol Biol Psychiatry*  
962 **100**, 109909 (2020).
- 963 40. A. Kassambara. (R package version 0.6.0., 2020).
- 964 41. A. Dumais *et al.*, Risk factors for suicide completion in major depression: a case-control  
965 study of impulsive and aggressive behaviors in men. *Am J Psychiatry* **162**, 2116-2124  
966 (2005).
- 967 42. L. M. Fiori *et al.*, miR-323a regulates ERBB4 and is involved in depression. *Mol*  
968 *Psychiatry* **26**, 4191-4204 (2021).
- 969 43. J. Lu *et al.*, Generation of serotonin neurons from human pluripotent stem cells. *Nat*  
970 *Biotechnol* **34**, 89-94 (2016).
- 971 44. J. P. Lopez *et al.*, miR-1202 is a primate-specific and brain-enriched microRNA involved  
972 in major depression and antidepressant treatment. *Nat Med* **20**, 764-768 (2014).
- 973 45. J. P. Guilloux, M. Seney, N. Edgar, E. Sibille, Integrated behavioral z-scoring increases  
974 the sensitivity and reliability of behavioral phenotyping in mice: relevance to  
975 emotionality and sex. *J Neurosci Methods* **197**, 21-31 (2011).

976

977





978

979

980 **Figure 1:** SNORD90 expression is associated with antidepressant treatment response.

981 **A** Two-way mixed multivariable ANOVA indicates a significant interaction between clinical

982 response (responders/non-responders; between-factor) and treatment course (T0/T8; within

983 factor). Nine snoRNAs displayed significant effects in the discovery cohort. Five out of the nine

984 snoRNAs were replicated in replication cohort 1 with SNORD90 and SNORA3 further


985 replicated in replication cohort 2. **B** Log<sub>2</sub> fold-change of the expression of SNORD90 before and

986 after antidepressant treatment for all three clinical cohorts. SNORD90 displayed a significantly

987 increased expression after eight weeks of antidepressant treatment specifically in those who  
988 responded. **C** Snord90 expression in the ACC of mice that underwent unpredictable chronic mild  
989 stress (UCMS) and antidepressant administration. **D** SNORD90 expression in human post-  
990 mortem ACC. Samples were separated based on presence or absence of antidepressant drug  
991 treatment. **E** SNORD90 expression in human neuronal cultures exposed to various psychotropic  
992 drugs. **C-E** Statistical analysis using one-way ANOVA with Bonferroni post-hoc (unless  
993 otherwise indicated on the graph). **B-E** All bar plots represent the mean with individual data  
994 points as dots. Error bars represent S.E.M. (\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ).

995

996



997


998

999 **Figure 2:** SNORD90 over-expression in mouse Cg1/2 induces anxiolytic and anti depressive-  
1000 like behaviors

1001 **A** Timeline of experimental procedure with time (weeks) in relation to behavioral testing.  
1002 Surgery for viral injection was performed followed by three weeks of recovery before behavioral  
1003 testing (left). Coronal diagram of the mouse brain representing viral injection site (center).  
1004 Representative images of GFP expression (green) indicating site specific expression of each  
1005 construct (right). **B** The open field test showing total distance traveled in meters. **C** The elevated  
1006 plus maze test with total time spent in the closed and open arms of the maze. **D** The splash test  
1007 with total grooming time. **E** The tail suspension test with total struggling time. **F** Emotionality z-  
1008 score integrating the EPM, SPL, and TST. **C-G** Statistical analysis using student's two-tailed t-  
1009 test. All bar plots represent the mean with individual data points as dots. Error bars represent  
1010 S.E.M. (\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ).

1011

1012



1013

1014

1015 **Figure 3: SNORD90 down-regulates NRG3**

1016 **A** Full sequence of mature SNORD90 transcript with highlighted regions, labeled predicted B.S.

1017 1 and predicted B.S. 2, which are predicted to bind to NRG3. Schematic representation of NRG3

1018 pre-mRNA transcript indicating regions on NRG3 where SNORD90 is predicted to bind. The


1019 color of the bracket corresponds to predicted B.S.-1 or predicted B.S.-2. **B** Expression of

1020 SNORD90 (left) and NRG3 (right) after over-expressing SNORD90 or scrambled controls

1021 (right). **C** Expression of SNORD90 (left) and NRG3 (right) after knocking-down SNORD90

1022 with antisense oligonucleotides (ASO) and scrambled ASO. **D** Schematic representation of co-  
1023 transfection of SNORD90 over-expression vector without target blockers (top) and with target  
1024 blockers (bottom). Target blockers were designed to bind to regions SNORD90 is predicted to  
1025 bind, consequently blocking SNORD90 from interacting with those regions on NRG3 (bottom).  
1026 **E** Expression of NRG3 after over-expression of SNORD90 and target blockers. Target blockers  
1027 were included one site at a time and all three sites together. **B-D, F** All bar plots represent the  
1028 mean with individual data points as dots. Error bars represent S.E.M. All statistical analysis  
1029 utilized a one-way ANOVA with Bonferroni post-hoc (\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ).  
1030

1031



1032

1033


1034 **Figure 4: SNORD90 is a guide RNA for RBM15B and increases m6A abundance on NRG3**

1035 **A** Abundance of SNORD90 (left) and canonical snoRNA (SNORD44; right) in RBM15B-IP and  
1036 fibrillarin-IP fractions. **B** Abundance of SNORD90 in RBM15B-IP (left) and fibrillarin-IP (right)  
1037 following over-expression of SNORD90 or scramble control. **C** Abundance of m6A  
1038 modifications on NRG3 mRNA (left) and NRG3 pre-mRNA (right) following over-expression of  
1039 SNORD90 or scramble controls. **D** Abundance of m6A modifications on NRG3 mRNA (left)  
1040 and NRG3 pre-mRNA (right) following SNORD90 overexpression with target blockers. **E**  
1041 Abundance of m6A modifications on NRG3 (left) and NRG3 expression (right) following  
1042 RBM15B knock-down (siRBM15B) or negative control (siControl) and SNORD90 over-  
1043 expression. **F** Same as E but on NRG3 pre-mRNA. **G** Expression of NRG3 after knocking-down  
1044 m6A reader proteins followed by over-expression of SNORD90. **H** Schematic overview of  
1045 SNORD90 regulation of NRG3 expression. SNORD90 interacts with m6A writer complex in the  
1046 nucleus and guides this complex onto NRG3 increasing m6A abundance. The increase in m6A  
1047 abundance is not recognized until NRG3 reaches the cytoplasm where it undergoes YTHDF2  
1048 mediated RNA decay. All bar plots represent the mean with individual data points as dots. Error  
1049 bars represent S.E.M. Statistical analysis utilized as follows: **A-B** Student's two-tailed t test. **E**  
1050 Pearson correlation. **C-D, F-H** One-way ANOVA with Bonferroni post-hoc (\* $p < 0.05$ , \*\* $p < 0.01$ ,  
1051 \*\*\* $p < 0.001$ ).

1052



1053



1054

1055

1056 **Figure 5:** SNORD90 induced down-regulation of Nrg3 increases glutamatergic

1057 neurotransmission

1058 **A** qPCR confirmation of Snord90 over-expression in cg1/2. **B** Nrg3 expression after Snord90

1059 over-expression. **C-E** Whole-cell patch-clamp recordings in Cg1/2 acute brain slices from mice

1060 over-expressing SNORD90 or scramble control. sEPSCs were recorded from pyramidal neurons

1061 at -70 mV. **A-C & E** Statistical analysis using student's two-tailed T-test. All bar plots represent

1062 the mean with individual data points as dots. Error bars represent S.E.M. (\*p<0.05, \*\*p<0.01,

1063 \*\*\*p<0.001).

1064

# Supplementary Materials for

## **SNORD90 induces glutamatergic signaling following treatment with monoaminergic antidepressants**

Rixing Lin<sup>†</sup>, Aron Kos<sup>†</sup>, Juan Pablo Lopez, Julien Dine, Pascal Ibrahim, Jennie Yang, Laura M. Fiori, Yair Ben-Efraim, Zahia Aouabed, Haruka Mitsuhashi, Tak Pan Wong, El Cherif Ibrahim, Catherine Belzung, Pierre Blier, Faranak Farzan, Benicio N. Frey, Raymond W. Lam, Roumen Milev, Daniel J. Müller, Sagar V. Parikh, Claudio Soares, Rudolf Uher, Corina Nagy, Naguib Mechawar, Jane A. Foster, Sidney H. Kennedy, Alon Chen\*, and Gustavo Turecki\*


<sup>†</sup>These authors contributed equally to this work  
\*Corresponding author. Email: [gustavo.turecki@mcgill.ca](mailto:gustavo.turecki@mcgill.ca)

### **This PDF file includes:**

Figs. S1 to S10


### **Other Supplementary Material for this manuscript includes the following:**

Table S1 to S10 (.xlsx)



**Supplementary Figure 1: SCARNA3 expression in human clinical cohorts (related to figure 1)**


Log2 fold-change of the expression of SCARNA3 before and after antidepressant treatment for all three clinical cohorts. SCARNA3 displayed inconsistent expression after eight weeks of antidepressant treatment.



**Supplementary Figure 2:** NRG3 expression negatively correlates with SNORD90 in the context of antidepressant (related to figure 1)

**A** Nrg3 expression in the ACC of mice that underwent unpredictable chronic mild stress (UCMS) and antidepressant administration. **B** NRG3 expression in human post-mortem ACC.

Samples were separated based on presence or absence of antidepressant drug treatment. **C** NRG3 expression in human neuronal cultures exposed to various psychotropic drugs. **D-F** Correlation between SNORD90 and NRG3 expression in each of the respective experiments listed in A-C. **G-I** SNORD90 (red) and NRG3 (black) fold change in relation to control conditions. SNORD90 and NRG3 displayed the most opposing direction of expression in groups exposed to antidepressants. **A-C** Statistical analysis using one-way ANOVA with Bonferroni post-hoc. **D-F** Pearson correlation. **G-I** Statistical analysis using two-way mixed ANOVA with Bonferroni post-hoc. All bar plots represent the mean with individual data points as dots. Error bars represent S.E.M. (\* $p < 0.05$ , \*\* $p < 0.01$ ).



### Supplementary Figure 3: SNORD90 over-expression in human NPCs (related to figure 3)

**A** Sequences of each over-expressed transcript. Red indicates scrambled sequence and black indicates wild-type sequence. Yellow highlight indicates where forward and reverse primers bind for qPCR quantification. Over-expression of SNORD90 WT transcript and seed scramble will be detected by our primers however full scramble will not. **B** Image of NPC 48hrs post-transfection. White is the expression of GFP to confirm successful transfection. **C** Quantification of NRG3 protein levels following SNORD90 over-expression. NRG3 protein levels were significantly reduced after SNORD90 over-expression (left). Western blots where samples were equally

distributed between two separate gels and randomly assigned a well (right). **D** Expression of NRG3 pre-mRNA following SNORD90 over-expression. **C-D** Statistical analysis using one-way ANOVA with Bonferroni post-hoc. All bar plots represent the mean with individual data points as dots. Error bars represent S.E.M. (\* $p < 0.05$ , \*\* $p < 0.01$ ).


### **Supplementary Figure 3C-source data**

Source data for western blots for supplementary figure 3C including original unedited files of each western blot.


A

SNORD90 Transcript


AAGTTTTCTAAGTGTCTAATGATGAATTCATAGGGCAGATTCGAGGTGAAAATTTAATTCATCACTGATACTCCTACTGTGGAATCTGAAGACACTTGAAAACGT



**B** SNORD90 ASO K.D. Screen  
F(5,30)=4.294, p=0.005 (Dunnett t)




**C** NRG3 pre-mRNA (SNORD90 O.E.)  
F(2,15)=2.627, p=0.105



#### Supplementary Figure 4: SNORD90 knock-down in human NPCs (related to figure 3)

**A** Schematic diagram indicating where each ASO is designed to bind onto SNORD90. **B** Screen of all four ASOs to determine which ASO produced the best knock-down of SNORD90. **C** Expression of NRG3 pre-mRNA after SNORD90 knock-down. **B-C** Statistical analysis using one-way ANOVA with Bonferroni post-hoc (unless otherwise indicated on the graph). All bar plots represent the mean with individual data points as dots. Error bars represent S.E.M. (\*p<0.05).






**Supplementary Figure 5:** SNORD90 over-expression and NRG3 target blockers (related to figure 3)


Expression of NRG3 pre-mRNA after SNORD90 over-expression followed by NRG3 target blockers. Statistical analysis using one-way ANOVA with Bonferroni post-hoc (unless otherwise indicated on the graph). All bar plots represent the mean with individual data points as dots.

Error bars represent S.E.M.




**Supplementary Figure 6:** m6A abundance on NRG3 is related to expression (related to figure 4)

**A** Correlation of total m6A abundance on NRG3 and NRG3 expression. **B** Correlation of total m6A abundance on NRG3 pre-mRNA and NRG3 pre-mRNA expression. **A-B** person correlation



**Supplementary Figure 7: RBM15B knock-down (related to figure 4)**

A qPCR validation of RBM15B knock-down using dsRNAs. **B-C** Correlation of total m6A abundance on NRG3 or NRG3 pre-mRNA and expression. **B-C** Person correlation. **A** Statistical analysis using one-way ANOVA with Bonferroni post-hoc. All bar plots represent the mean with individual data points as dots. Error bars represent S.E.M. (\*\* $p < 0.01$ ).




### Supplementary Figure 8: m6A-reader knock-down (related to figure 4)

**A-E** qPCR validation of each respective m6A-reader knock-down using dsiRNAs. **A-E**

Statistical analysis using one-way ANOVA with Bonferroni post-hoc. All bar plots represent the mean with individual data points as dots. Error bars represent S.E.M. (\* p<0.05, \*\*p<0.01,

\*\*\*p<0.001, \*\*\*\*p<0.0001).



**Supplementary Figure 9:** Expression of NRG3 pre-mRNA after m6A-reader knock-down (related to figure 4)

Expression of NRG3 pre-mRNA following m6A-reader knock-down and SNORD90 over-expression. Statistical analysis using one-way ANOVA with Bonferroni post-hoc. All bar plots represent the mean with individual data points as dots. Error bars represent S.E.M. (\*\*p<0.01).



**Supplementary Figure 10: Snord90-nrg3 interaction is conserved in mice (related to figure 5)**

Schematic diagram showing predicted interaction sites between Snord90 and Nrg3 in mice

## **Supplementary Table 1 to 10**

**Supp. Table 1 (separate file).** Summary statistics for small RNA sequencing analysis in human clinical discovery cohort

**Supp. Table 2 (separate file).** Summary statistics for small RNA sequencing analysis in human clinical replication 1 cohort

**Supp. Table 3 (separate file).** Summary statistics for small RNA sequencing analysis in human clinical replication 2 cohort

**Supp. Table 4 (separate file).** SNORD90 BLAST alignment results

**Supp. Table 5 (separate file).** SNORD90 PLEXY target prediction results (human)

**Supp. Table 6 (separate file).** SNORD90 RNA binding protein motif prediction results

**Supp. Table 7 (separate file).** SNORD90 PLEXY target prediction results (mouse)

**Supp. Table 8 (separate file).** qPCR primer sequences

**Supp. Table 9 (separate file).** ASO sequences

**Supp. Table 10 (separate file).** dsRNA sequences